While the approval of the first DTC pharmacogenomics test provides exciting opportunities to educate the general public about the clinical value of pharmacogenomics, it also must be viewed with caution.
Is it time for us to use pharmacogenomics to find safe and effective doses of tamoxifen for patients — optimizing clinical outcomes with minimal side effects? Dr. Jennifer Hockings discusses.
Pharmacogenomic testing may one day be feasible for ADHD. Jennifer Hockings, PharmD, PhD, explains a growing body of research to-date and what additional work is still needed to make it become a reality.
Knowing how patients metabolize medication could be a powerful tool for doctors seeking the right pain remedies for patients. Pharmacogenomics is a growing industry and one that needs further research to be useful says a Cleveland Clinic pain specialist.